DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Phase 3

Completed

Conditions: Refractory Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: melphalan
Drug: amifostine trihydrate
Procedure: peripheral blood stem cell transplantation
Genetic: fluorescence in situ hybridization
Procedure: bone marrow ablation with stem cell support

First Posted Date: 2005-09-22

Last Posted Date: 2015-08-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 130

Registration Number: NCT00217438

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 1 locations

Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Peritoneal Cavity Cancer

First Posted Date: 2005-09-22

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00217568

Locations: 🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States
🇺🇸
Pacific Gynecology Specialists, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

First Posted Date: 2005-09-22

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00217555

Locations: 🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States

Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2005-09-22

Last Posted Date: 2010-09-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00217386

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Olympic Medical Center, Port Angeles, Washington, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

and more 1 locations

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

First Posted Date: 2005-09-22

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00217529

Locations: 🇺🇸
Pacific Gynecology Specialists, Seattle, Washington, United States
🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon

Phase 2

Completed

Conditions: HIV-1 and HSV-2 Coinfection
HIV Infections

Interventions: Drug: Acyclovir

First Posted Date: 2005-09-21

Last Posted Date: 2011-12-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00209313

Locations: 🇨🇲
Hospital Central, Yaounde, Cameroon

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

Phase 3

Completed

Conditions: VZV Infection After Bone Marrow Transplantation

First Posted Date: 2005-09-21

Last Posted Date: 2007-12-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 120

Registration Number: NCT00209352

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Phase 2

Completed

Conditions: Stage II Multiple Myeloma
Stage I Multiple Myeloma
Stage III Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: clarithromycin
Drug: thalidomide
Drug: dexamethasone

First Posted Date: 2005-09-16

Last Posted Date: 2017-06-26

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00182663

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor

Phase 1

Completed

Conditions: Anemia, Aplastic

First Posted Date: 2005-09-05

Last Posted Date: 2008-04-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 85

Registration Number: NCT00144729

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington, United States

Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer

Completed

Conditions: Leukemia
Lymphoma
Myelodysplastic Syndromes
Quality of Life

First Posted Date: 2005-08-04

Last Posted Date: 2013-05-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 750

Registration Number: NCT00126477

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy